Parasitologic Impact of Different Mass Drug Administration Strategies Against Schistosoma Mansoni in Endemic Areas of Mwanza Region, Tanzania, Where Prevalence is 25% or Above
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 37,500
- 试验地点
- 1
- 主要终点
- Effect of Mass drug administration on prevalence and intensity of Schistosoma mansoni among children and adults
研究概览
简要总结
The objective of this study is to determine the strategy for mass drug administration (MDA) which provides the greatest reductions in prevalence and intensity of Schistosoma mansoni in school-aged children after 4 years of intervention.
详细描述
Intestinal schistosomiasis is caused by the blood-dwelling flatworm Schistosoma mansoni. Despite the increasing focus on the use of praziquantel against schistosomiasis infections for the last three decades many areas in Sub-Saharan Africa still have high prevalences and intensities of schistosomiasis especially among school-age children. This is true for the area of Mwanza Region of Tanzania adjacent to Lake Victoria. The study is a six arm study and includes 150 communities (25 in each arm). From each community 100 school children (aged 9-12 years), 100 first year students (aged 7-8 years) and 50 adults (aged 20-55 years) are included, diagnosed and treated with praziquantel using strategies composing of a mixture of community wide treatment (CWT), school-based treatment (SBT) and years without treatment (-T). The 100 school children provided stool specimens on three consecutive days, while the 100 first year students and 50 adults with few exceptions only provided one specimen. The treatment strategies during the 4 years for the different arms are as follows: Arm 1: CWT, CWT, CWT, CWT; Arm 2: CWT, CWT, SBT, SBT; Arm 3: CWT, CWT -T, -T; Arm 4: SBT, SBT, SBT, SBT; Arm 5: SBT, SBT, -T, -T; Arm 6: SBT, -T, SBT, -T.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 7 Years 至 55 Years(Child, Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All school children and adults who consent to participate can be included
排除标准
- •Those not consenting or with any chronic disease not related to schistosomiasis will be excluded
研究组 & 干预措施
MDA once a year
Community wide treatment (CWT) once a year for four years with single dose praziquantel 40mg/kg
干预措施: Praziquantel (Drug)
MDA 2nd year CWT follwed by 2 years SBT
Treatment with praziquantel as arm 1 given by two years of community wide treatment (CWT) followed by two years of school-based treatment (SBT)
干预措施: Praziquantel (Drug)
Praziquantel every second year CWT
Treatment with praziquantel given every second year as CWT
干预措施: Praziquantel (Drug)
MDA once a year SBT
Treatment with praziquantel as above given as 4 years of SBT
干预措施: Praziquantel (Drug)
MDA given for 2 years as SBT
Treatment with praziquantel as above given for 2 years as SBT followed by 2 years without MDA
干预措施: Praziquantel (Drug)
MDA as SBT 1year and 1 year without MDA
Treatment with praziquantel given as one years of SBT alternating with one year without treatment
干预措施: Praziquantel (Drug)
结局指标
主要结局
Effect of Mass drug administration on prevalence and intensity of Schistosoma mansoni among children and adults
时间窗: May -October 2016 (5 months)
Prevalence and intensity of Schistosoma mansoni
次要结局
- Mass drug administration coverage(May -October 2016 (5 months))
研究者
Pascal Magnussen
Associate Professor
DBL -Institute for Health Research and Development
